Several new antiepileptic drugs and devices aimed at preventing or suppressing seizure have achieved results with better management of side effects than is seen with existing therapeutic agents, according to Dr. Jacqueline A. French.
“You may hear many people saying that we have made no progress whatsoever” in epilepsy therapy, said Dr. French, professor of neurology and codirector of epilepsy research and clinical trials at New York University.
Indeed, about a third of patients were considered “treatment resistant” during the era of bromide therapy for epilepsy, and about the same proportion of patients are considered “treatment resistant” today, Dr. French said at the meeting.
However, she explained that far better management of side effects has been achieved, resulting in better overall management and fewer total seizures in today’s patients.
One measure of that success is the increasingly challenging task of finding patients who experience four or more seizures a month, thereby qualifying for clinical trials, Dr. French noted.
In the pipeline today are what she called “evolutionary” drugs – new twists on mechanisms found in existing therapeutic agents that enhance their safety, tolerability, or potency – and “revolutionary” drugs characterized by novel mechanisms.
The following are among the potential options on the horizon for clinical practice.
Evolutionary Drugs
Clobazam, a benzodiazepine widely used in Canada and Europe, was approved by the Food and Drug Administration on Oct. 21 as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. The drug will be marketed under the trade name Onfi. Dr. French said the agent is believed to produce less tachyphylaxis than others in its class.
Brivaracetam, an analogue of levetiracetam, is hoped to exceed the potency of its predecessor while reducing side effects of irritability and depression. The first study of the agent in a small group of expert sites was “extremely promising,” but a second, global trial failed. A third trial is underway, Dr. French said, to clarify results.
Eslicarbazepine is a third-generation version of carbamazepine, “the drug we love to hate,” she said. Approved in Europe, this agent has a short half-life and is dosed once daily. Its improved side effect profile is the main draw, especially with regard to body weight, cholesterol, glucose, and hepatic effects.
Revolutionary Drugs
Ezogabine (Potiga), a novel potassium channel blocker, selectively activates the KCNQ channel, resulting in “stabilization of hyperexcitable neuronal cells.” In clinical trials in patients with partial-onset seizures, the drug showed “no plateau of efficacy,” but adverse events have limited its dosage.
Perampanel is the first drug to be submitted to the FDA based on an excitation mechanism rather than membrane inhibition or stabilization. The drug is a highly selective, noncompetitive, antiglutamate receptor antagonist. “It’s pretty close to getting to the clinic,” she said at the meeting.
VX-765 is “something completely different,” said Dr. French: an interleukin-converting enzyme inhibitor developed at the behest of researchers based on their hypothesis that modulation of proinflammatory cytokines might play a major role in seizure suppression. One human proof-of-concept trial has been completed, and another trial will be launched soon. As in animal studies, seizures were reduced following a delay period in the initial human study, she said.
Devices
Medtronic’s Deep Brain Stimulator, a device currently under FDA review, produces shocks at regular, timed intervals following implantation in the thalamus. “Patients can self-trigger the device if they feel a seizure coming on,” she said. In studies of the Deep Brain Stimulator, both actively treated and sham groups had a reduction in seizures early on, but efficacy improved over time in the treated group, and the device is believed by proponents to be most efficacious as long as 2 years after implantation.
NeuroPace’s Responsive Neurostimulator system, a “smart” device, countershocks the epileptic focus, and is similarly believed to lead to “better and better and better” seizure control over months of use, Dr. French said.
NeuroVista’s Seizure Advisory System is another implantable device, this one acting on a complex algorithm of input from the brain to warn patients in advance of impending seizures. Should a patient receive a signal from the device, he or she might have an hour to prepare for a seizure, reducing safety concerns and heightening patients’ sense of empowerment over the disease.
Dr. French is president of the Epilepsy Study Consortium, which receives funding and provides consultation to a large number of pharmaceutical companies, including those represented in her talk. As a nonprofit organization, the Epilepsy Study Consortium’s members receive no personal compensation from pharmaceutical companies.
Drugs on the horizon for clinical practice build on existing mechanisms or operate through novel ones. Source DR. FRENCH